Literature DB >> 8031063

Penetration of clarithromycin into lung tissues from patients undergoing lung resection.

D N Fish1, M H Gotfried, L H Danziger, K A Rodvold.   

Abstract

The concentrations of clarithromycin and its active principal metabolite, 14-(R)-hydroxy-clarithromycin, were determined in lung tissue obtained during lung resection and compared with concomitant concentrations in plasma. Concentrations of the parent and metabolite were determined by high-performance liquid chromatography. The 15 patients studied were given 500 mg orally every 12 h for a minimum of five doses to achieve steady-state concentrations. The mean concentrations of clarithromycin and 14-(R)-hydroxy-clarithromycin in plasma just prior to the final dose were 1.38 and 0.67 micrograms/ml, respectively, and those 4 h after the final dose (at the time of lung resection) were 1.89 and 0.80 microgram/mL, respectively. The concentrations of the parent and metabolite in lung tissue at the time of lung resection averaged 54.3 and 5.12 micrograms/g, respectively, with a mean calculated ratio of concentrations of the parent to metabolite being 11.3 in lung tissue and 2.4 in plasma. Clarithromycin and its active metabolite are extensively distributed into human lung tissue.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031063      PMCID: PMC284560          DOI: 10.1128/AAC.38.4.876

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.

Authors:  S Y Chu; L T Sennello; R C Sonders
Journal:  J Chromatogr       Date:  1991-11-15

3.  A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' disease.

Authors:  S Kohno; H Koga; K Yamaguchi; M Masaki; Y Inoue; Y Dotsu; Y Masuyama; T Hayashi; M Hirota; A Saito
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

4.  Penetration of macrolides into human polymorphonuclear leucocytes.

Authors:  M Ishiguro; H Koga; S Kohno; T Hayashi; K Yamaguchi; M Hirota
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

5.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

6.  Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

Authors:  N X Chin; N M Neu; P Labthavikul; G Saha; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

7.  The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans.

Authors:  F Fraschini; F Scaglione; G Pintucci; G Maccarinelli; S Dugnani; G Demartini
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

8.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 9.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  16 in total

1.  Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae.

Authors:  K L Bergman; K M Olsen; T E Peddicord; P D Fey; M E Rupp
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.

Authors:  Friederike Traunmüller; Markus Zeitlinger; Petra Zeleny; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

Review 3.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 4.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

5.  Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.

Authors:  K A Rodvold; M H Gotfried; L H Danziger; R J Servi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.

Authors:  Kaitlyn Schaaf; Virginia Hayley; Alexander Speer; Frank Wolschendorf; Michael Niederweis; Olaf Kutsch; Jim Sun
Journal:  Assay Drug Dev Technol       Date:  2016-06-21       Impact factor: 1.738

Review 7.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.

Authors:  Jun Shi; Guy Montay; Vijay O Bhargava
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

9.  Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Antituberculosis activity of clarithromycin.

Authors:  J Luna-Herrera; V M Reddy; D Daneluzzi; P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.